Bio-Gene Technology Ltd. (AU:BGT)
ASX:BGT
BGT Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume38.03K
Average Volume (3M)988.87K
Market Cap
AU$9.46M
Enterprise ValueAU$8.68M
Total Cash (Recent Filing)AU$1.08M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding305,061,100
10 Day Avg. Volume246,330
30 Day Avg. Volume988,871
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.08
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces solvency risk and preserves strategic flexibility for a loss-making biotech. Lower interest burdens lengthen runway relative to highly leveraged peers, making external financing less urgent in the near term and improving the company’s ability to prioritize R&D or partnership-led commercialization.
Licensing-based ModelA licensing and royalty model can scale without large capital expenditures, enabling revenue participation via partners and distributors. This business model supports margin leverage once products are commercialized and reduces the need to build costly manufacturing capacity in-house.
Broad Application FocusTechnology applicable across agriculture, public health and pest control diversifies addressable markets and reduces single-market dependency. Multi-sector applicability increases commercial partner appeal and potential revenue streams if compounds achieve regulatory and market acceptance.
Bears Say
Zero Reported RevenueReporting no revenue in the latest fiscal year indicates products have not generated commercial sales or licensing income, undermining self-sufficiency. Without clear commercialization progress, the company remains dependent on external funding to validate and monetize its IP over the medium term.
Sustained Cash BurnConsistent negative operating and free cash flow depletes reserves and necessitates recurrent capital raises. Persistent cash burn constrains R&D investment pacing, clinical or regulatory activities, and commercialization efforts, increasing dilution risk and limiting long-term execution flexibility.
Eroding Equity BaseA contracting equity base reflects cumulative losses and likely prior dilution, weakening the balance sheet's shock absorption. Reduced shareholders’ equity increases vulnerability to adverse outcomes, raises future financing costs, and can limit the company’s ability to pursue strategic transactions or large-scale commercialization.
Bio-Gene Technology Ltd. News
BGT FAQ
What was Bio-Gene Technology Ltd.’s price range in the past 12 months?
Bio-Gene Technology Ltd. lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Bio-Gene Technology Ltd.’s market cap?
Bio-Gene Technology Ltd.’s market cap is AU$9.46M.
When is Bio-Gene Technology Ltd.’s upcoming earnings report date?
Bio-Gene Technology Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 132 days.
How were Bio-Gene Technology Ltd.’s earnings last quarter?
Bio-Gene Technology Ltd. released its earnings results on Feb 23, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Bio-Gene Technology Ltd. overvalued?
According to Wall Street analysts Bio-Gene Technology Ltd.’s price is currently Overvalued.
Does Bio-Gene Technology Ltd. pay dividends?
Bio-Gene Technology Ltd. does not currently pay dividends.
What is Bio-Gene Technology Ltd.’s EPS estimate?
Bio-Gene Technology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Gene Technology Ltd. have?
Bio-Gene Technology Ltd. has 305,061,100 shares outstanding.
What happened to Bio-Gene Technology Ltd.’s price movement after its last earnings report?
Bio-Gene Technology Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of Bio-Gene Technology Ltd.?
Currently, no hedge funds are holding shares in AU:BGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Gene Technology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.63%
12-Months-Change
Fundamentals
Return on Equity
-140.35%
Trailing 12-Months
Asset Growth
-21.07%
Trailing 12-Months
Company Description
Bio-Gene Technology Ltd.
Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.
Technical Analysis
Zelira Therapeutics
―
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
AdAlta Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---